Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Taysha Gene Therapies, Inc. (TSHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.0000+0.0400 (+1.01%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.9600
Open4.0400
Bid3.9400 x 800
Ask4.5200 x 800
Day's Range3.7400 - 4.0897
52 Week Range2.3300 - 25.4400
Volume120,984
Avg. Volume344,682
Market Cap153.896M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.8080
Earnings DateMar 01, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.20
  • GlobeNewswire

    Taysha Gene Therapies Announces Annual Stockholder Meeting

    The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ETDALLAS, June 13, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that its annual stockholder meeting will be held on Friday, June 17, 2022 at 10 am ET via

  • GlobeNewswire

    Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention

    Jefferies Healthcare Conference on June 8, 2022 at 9:30 am ET Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 11:20 am PT BIO International Convention on June 15, 2022 at 11:00 am PT JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 pm ET DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea

  • Motley Fool

    Taysha Gene Therapies, Inc. (TSHA) Q1 2022 Earnings Call Transcript

    Joining me on today's call are RA Session II, Taysha's president, founder, and CEO; Dr. Suyash Prasad, chief medical officer and head of R&D and Kamran Alam, chief financial officer. After formal remarks, we will conduct a question-and-answer session, and instructions will follow at that time.

Advertisement
Advertisement